Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesBernard Zinman, Silvio E. Inzucchi|New England Journal of Medicine|2015Cited by 11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyVlado Perkovic, Kenneth W. Mahaffey, Bernard Zinman et al.|New England Journal of Medicine|2019Cited by 6k
Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesChristoph Wanner, Bernard Zinman|New England Journal of Medicine|2016Cited by 3.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesRury R. Holman, Adrian F. Hernandez, M. Angelyn Bethel et al.|New England Journal of Medicine|2017Cited by 2.1k
Impaired Fasting Glucose and Impaired Glucose ToleranceDavid M. Nathan, Bernard Zinman|Diabetes Care|2007Cited by 1.4k